R07 Stock Chart & Stats
€0.27
<€0.01(3.01%)
At close: 4:00 PM EDT
€0.27
<€0.01(3.01%)
Day’s Range― - ―
52-Week Range€0.25 - €0.35
Previous CloseN/A
Volume0.00
Average Volume (3M)12.00
Market Cap
€17.28M
Enterprise Value€46.33M
Total Cash (Recent Filing)€2.96M
Total Debt (Recent Filing)€15.58M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Nov 18, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding67,578,920
10 Day Avg. Volume0
30 Day Avg. Volume12
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)0.71
Price to Sales (P/S)0.53
P/FCF Ratio-2.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.74Price Target Upside172.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€47.64M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid revenue expansion shows growing demand and improving distribution for Rubicon’s premium portfolio. The record quarterly result, combined with multi-year scaling, provides a stronger base for operating leverage and supports continued investment in brands, production capacity, and market expansion.
Premium Brand And Market PositionLeadership in premium flower and recognition for the flagship brand indicate meaningful consumer and trade acceptance. A differentiated branded portfolio can support pricing quality, repeat demand, and distribution access, strengthening Rubicon’s competitive position beyond commodity cannabis sales.
Yield And Capacity ExpansionHigher Pacifica yields demonstrate tangible cultivation and genetics improvements that can increase available product without proportionate facility expansion. The planned capacity pathway also provides room for volume growth, better fixed-cost absorption, and improved supply consistency as demand develops.
Bears Say
Severe Gross Margin CompressionThe sharp margin deterioration indicates that recent revenue growth is not translating reliably into operating profit. Sustained pricing, mix, or cost pressure could limit the benefits of scale, weaken reinvestment capacity, and make management’s targeted 40%+ margins dependent on successful execution.
Persistent Negative Cash GenerationNegative operating and free cash flow show that the business is not yet consistently funding operations and investment internally. Continued cash consumption raises dependence on financing or working-capital management, reducing flexibility if growth initiatives take longer to produce margin and EBITDA benefits.
Cascadia Ramp-Up Execution RiskCascadia is important to the company’s production and margin expansion plan, yet its early yields remain below target. Delayed optimization could defer expected volume, spread fixed costs over fewer units, and prolong start-up expenses, making the H2 2026 and 2027 improvement plan harder to achieve.
Rubicon Organics News
R07 FAQ
What was Rubicon Organics Inc’s price range in the past 12 months?
Rubicon Organics Inc lowest stock price was €0.25 and its highest was €0.35 in the past 12 months.
What is Rubicon Organics Inc’s market cap?
Rubicon Organics Inc’s market cap is €17.28M.
When is Rubicon Organics Inc’s upcoming earnings report date?
Rubicon Organics Inc’s upcoming earnings report date is Nov 18, 2026 which is in 20 days.
How were Rubicon Organics Inc’s earnings last quarter?
Rubicon Organics Inc released its earnings results on Aug 11, 2026. The company reported €0.006 earnings per share for the quarter, beating the consensus estimate of -€0.003 by €0.01.
Is Rubicon Organics Inc overvalued?
According to Wall Street analysts Rubicon Organics Inc’s price is currently Undervalued.
Does Rubicon Organics Inc pay dividends?
Rubicon Organics Inc does not currently pay dividends.
What is Rubicon Organics Inc’s EPS estimate?
Rubicon Organics Inc’s EPS estimate is 0.01.
How many shares outstanding does Rubicon Organics Inc have?
Rubicon Organics Inc has 67,578,920 shares outstanding.
What happened to Rubicon Organics Inc’s price movement after its last earnings report?
Rubicon Organics Inc reported an EPS of €0.006 in its last earnings report, beating expectations of -€0.003. Following the earnings report the stock price went down -10.909%.
Which hedge fund is a major shareholder of Rubicon Organics Inc?
Currently, no hedge funds are holding shares in DE:R07
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rubicon Organics Inc
Rubicon Organics Inc. cultivates, processes, and distributes organic cannabis products for both recreational and medicinal consumers across Canada. The company markets its organic cannabis through its proprietary labels as well as various licensed brands. Founded in 2015, Rubicon Organics Inc. maintains its headquarters in Vancouver, Canada.
R07 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear operational momentum (record revenue, 20% yield gains at Pacifica, Cascadia brought online and certified, market share gains, and margin improvement potential excluding Cascadia start-up costs) alongside typical early-stage scaling challenges (Cascadia yields below targets, modest Q2 Cascadia revenue, higher SG&A, slight YoY decline in adjusted EBITDA, and limited cash). Management offered a coherent plan (yield optimization, in-house extraction, automation, portfolio optimization, international expansion) and expects margin and EBITDA ramp in H2 2026 into 2027. Overall, positives (revenue growth, operational wins, brand strength, certifications) materially outweigh the near-term costs and execution risks.View all DE:R07 earnings summariesR07 Stock 12 Month Forecast
Average Price Target
€0.74
▲(172.28% Upside)